Drugs /

abbv-cls-484

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for abbv-cls-484

Abbv-cls-484 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating abbv-cls-484, 1 is phase 1 (1 open).

PD-L1 Expression (CPS >= 1) is the most frequent biomarker inclusion criterion for abbv-cls-484 clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and malignant solid tumor are the most common diseases being investigated in abbv-cls-484 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Abbv-Cls-484
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating abbv-cls-484 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
PTPN2

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.